Also found in: Dictionary, Thesaurus, Wikipedia.


a sulfonylurea used as a hypoglycemic in patients with type 2 diabetes mellitus whose blood glucose cannot be controlled by diet and exercise alone; administered orally.


Glibenese (UK), Glucotrol, Glucotrol XL, Minodiab (UK)

Pharmacologic class: Sulfonylurea

Therapeutic class: Hypoglycemic

Pregnancy risk category C


Lowers blood glucose level by stimulating insulin release from pancreas, increasing insulin sensitivity at receptor sites, and decreasing hepatic glucose production. Also increases peripheral tissue sensitivity to insulin and causes mild diuresis.


Tablets: 5 mg, 10 mg

Tablets (extended-release): 5 mg, 10 mg

Indications and dosages

To control blood glucose in type 2 (non-insulin-dependent) diabetes mellitus in patients who have some pancreatic function and don't respond to diet therapy

Adults: 5 mg/day P.O. initially, increased as needed after several days (range is 2.5 to 40 mg/day). Give extended-release tablet once daily; maximum dosage is 20 mg/day. Give daily dosage above 15 mg in two divided doses.

Conversion from insulin therapy

Adults: With insulin dosage above 20 units/day, start with usual glipizide dosage and reduce insulin dosage by 50%. With insulin dosage of 20 units/day or less, insulin may be discontinued when glipizide therapy starts.

Dosage adjustment

• Hepatic or renal impairment
• Elderly patients


• Hypersensitivity to drug
• Severe renal, hepatic, thyroid, or other endocrine disease
• Uncontrolled infection, serious burns, or trauma
• Diabetic ketoacidosis
• Pregnancy or breastfeeding


Use cautiously in:
• mild to moderate hepatic, renal, or cardiovascular disease; impaired thyroid, pituitary, or adrenal function
• elderly patients.


• Check baseline creatinine level for normal renal function before giving first dose.
• Give daily dose (extended-release) at breakfast.
• Administer immediate-release tablets 30 minutes before a meal (preferably breakfast). If patient takes two daily doses, give second dose before dinner.

Adverse reactions

CNS: dizziness, drowsiness, headache, weakness

CV: increased CV mortality risk

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, cramps, heartburn, epigastric distress, anorexia

Hematologic: aplastic anemia, agranulocytosis, leukopenia, pancytopenia, thrombocytopenia

Hepatic: cholestatic jaundice, hepatitis

Metabolic: hyponatremia, hypoglycemia

Skin: rash, pruritus, erythema, urticaria, eczema, angioedema, photosensitivity

Other: increased appetite


Drug-drug.Androgens (such as testosterone), chloramphenicol, clofibrate, guanethidine, MAO inhibitors, nonsteroidal anti-inflammatory drugs (except diclofenac), salicylates, sulfonamides, tricyclic antidepressants: increased risk of hypoglycemia

Beta-adrenergic blockers: altered response to glipizide, requiring dosage change; prolonged hypoglycemia (with nonselective beta blockers)

Calcium channel blockers, corticosteroids, estrogens, hydantoins, hormonal contraceptives, isoniazid, nicotinic acid, phenothiazines, phenytoin, rifampin, sympathomimetics, thiazide diuretics, thyroid preparations: decreased hypoglycemic effect

Warfarin: initially increased, then decreased, effects of both drugs

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, cholesterol: increased values

Glucose, granulocytes, hemoglobin, platelets, white blood cells: decreased values

Drug-herbs.Aloe (oral), bitter melon, burdock, chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek: additive hypoglycemic effects

Glucosamine: impaired glycemic control

Drug-behaviors.Alcohol use: disulfiram-like reaction

Patient monitoring

• Monitor blood glucose level, especially during periods of increased stress.
• Evaluate CBC and renal function tests.
• If patient is ill or has abnormal laboratory values, monitor electrolyte, ketone, glucose, pH, lactate dehydrogenase, and pyruvate levels.
• Monitor cardiovascular status.

Patient teaching

• Advise patient to take daily dose of extended-release tablets with breakfast or immediate-release tablet 30 minutes before breakfast (and second dose, if prescribed, before dinner).
• Advise patient to monitor blood glucose level as instructed by prescriber.
• Tell patient he may need supplemental insulin during times of stress or when he can't maintain adequate oral intake.
• Teach patient how to recognize signs and symptoms of hypoglycemia and hyperglycemia.
• Stress importance of diet and exercise to help control diabetes.
• Instruct patient to wear or carry medical identification describing his condition.
• Advise patient to keep sugar source at hand at all times in case of hypoglycemia.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Tell patient he'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.


/glip·i·zide/ (glip´ĭ-zīd) a sulfonylurea used as a hypoglycemic in the treatment of type 2 diabetes mellitus.


A sulfonylurea drug, C21H27N5O4S, used to treat type 2 diabetes.


an oral antidiabetic drug.
indications It is prescribed as an adjunct to diet and exercise to lower blood glucose levels of patients with type 2 (non-insulin-dependent) diabetes mellitus.
contraindications The dosage may have to be adjusted for patients who are taking drugs such as diuretics that increase blood glucose levels; elderly, debilitated, or malnourished patients are at risk of development of hypoglycemia.
adverse effects Among the most serious adverse effects are nausea, heartburn, and skin allergies.


Glucotrol® Therapeutics A sulfonylurea used to control insulin in type 2 DM. See Diabetes mellitus.


A SULPHONYLUREA drug used to treat maturity onset (Type II) DIABETES. Brand names are Glibenese and Minodiab.

glipizide (glip´izīd),

n brand name: Glucotrol;
drug class: oral antidiabetic (second generation);
action: causes functioning β cells in pancrease to release insulin, leading to a drop in blood glucose levels;
use: stable adult-onset diabetes mellitus (type 2).


a second generation sulfonylurea derivative, used as an oral hypoglycemia agent in the treatment of diabetes mellitus, most commonly in cats.
References in periodicals archive ?
9) In the absence of diagnosis information, a prescription for glipizide was presumed to represent a diagnosis of type 2 diabetes (for which it is indicated).
Glipizide is a sulfonylurea that lowers blood sugar by stimulating the pancreatic beta cells to release insulin regardless of glucose levels.
Glipizide and Metformin Hydrochloride Tablets are the generic version of Bristol Myers Squibb's Metaglip(TM) Tablets.
5 kg) from baseline at 52 weeks, while patients treated with glipizide experienced significant weight gain (mean +1.
And glibenclamide, gliquidone, glipizide and glimepiride are the common drugs in the class of sulfonylurea.
About 60 in 100,000 of those who take sulfonylurea drugs - such as glipizide (Glucotrol) -- would be expected to develop bladder cancer.
Additionally, both the Et0Ac and n-BuOH fractions induced-insulin secretion, but Et0Ac induced an early (at 15 min) and late (at 60 min) biphasic peak of insulin secretion similar to glipizide stimulatory effect.
Insulin remains the gold standard, but other oral agents, such as glipizide, glyburide, and metformin, have been effective in selected cases.
The prescribed sulfonylurea drugs were: glipizide 5mg/day, glimepride 1-2 mg/day or glyburide 2.
Of this last category, 72 per cent of the products were in the Drug Price Control Order ( DPCO) regime, including vitamin B complex, anti- diabetic Glipizide and anti- TB drug Rifampicin, among others.
A one-year study of an experimental diabetes drug made by Bristol-Myers Squibb and AstraZeneca PLC showed it was no worse at controlling blood sugar levels than an older drug called glipizide, the companies said yesterday.
Glimepiride (Amaryl[R]), glipizide (Glucotrol[R]), and glyburide (Micronase[R], Glynase[R], DiaBeta[R]), long-acting sulfonylureas, stimulate the pancreas to secrete insulin.